EHA 2019 | Anti-CD47 antibodies & azacitidine for AML and MDS

David Sallman

David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses the use of anti-CD47 antibodies in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video